Min-Jung Lee

National Institutes of Health — United States

Medicine · Health Sciences

37h-index4.9kcitations324works2.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(54), Chronic Myeloid Leukemia Treatments(41), Bladder and Urothelial Cancer Treatments(35), Renal cell carcinoma treatment(34), Colorectal Cancer Treatments and Studies(34)

Publications324 total

Topoisomerase III-beta protects from immune dysregulation and tumorigenesis
Science Advances·2025· 1 citedOpen Access
A Phase <scp>II</scp> Pilot Study of Anti‐ <scp>PD</scp> ‐ <scp>L1</scp> , Durvalumab, and a <scp>PARP</scp> Inhibitor, Olaparib in Patients With Metastatic Triple‐Negative Breast Cancer With or Without Germline BRCA Mutation
Cancer Medicine·2025Open Access
Strain-Level Differences of <i>Bifidobacterium breve</i> in the Gut Microbiome between Infants with and without Atopic Dermatitis: Insights from Genome Analysis and Immune Assays
Journal of Microbiology and Biotechnology·2025Open Access
Supplementary Figure S4 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
2025Open Access
Supplementary Figure S3 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
2025Open Access
Supplementary Table S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
2025Open Access
Supplementary Table S2 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
2025Open Access
Supplementary Figure S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
2025Open Access
Supplementary Data S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
2025Open Access
Supplementary Figure S2 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
2025Open Access
Age- and Sex-Specific Gut Microbiome Alterations in IgAN: Implications for Disease Pathogenesis and Progression
Journal of the American Society of Nephrology·2025
Longitudinal gut microbiota dynamics in Antarctic research mission crews
Frontiers in Microbiology·2025· 5 citedOpen Access
Abstract CT086: Phase II study of Minnelide for patients with adenosquamous carcinoma of the pancreas (ASCP)
Cancer Research·2025
Abstract 3771: Non invasive monitoring of relapsed SCLC using cell free fragmentomes and peripheral blood immunophenotyping
Cancer Research·2025
Tm4sf19 inhibition ameliorates inflammation and bone destruction in collagen-induced arthritis by suppressing TLR4-mediated inflammatory signaling and abnormal osteoclast activation
Bone Research·2025· 6 citedOpen Access
Supplementary Table S2 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
2024Open Access
Supplementary Figure S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
2024Open Access
Data from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
2024Open Access
Supplementary Table S2 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
2024Open Access
Supplementary Data S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
2024Open Access
page 1 of 17Next →

Frequent Co-authors

Jane B. Trepel(38), Sunmin Lee(16), Seth M. Steinberg(10), William D. Figg(9), Len Neckers(7), Yusuke Tomita(6), Akira Yuno(6), Kristin Beebe(5), James L. Gulley(5), Shinji Tsutsumi(4), Leonard Μ. Neckers(4), Eun Joo Chung(4), Maria J. Merino(4), Christophe E. Redon(4), James H. Doroshow(4), Shivaani Kummar(4), W. Marston Linehan(4), Howard L. Parnes(4), William L. Dahut(4), Wanping Xu(3)